新发性和复发性脑膜炎的风险与结性脊髓炎的不同生物药物:一个网络元分析
Xu Zhao1,2,3, Qingqing Xie2,3, Xinyi He1,2,3
1Department of Rheumatology and Immunology, Beijing Anzhen Nanchong Hospital of Capital Medical University, Nanchong Central Hospital, Sichuan, Nanchong, China.
Frontiers in immunology
|July 7, 2025
概括
生物药物如JAK抑制剂和比梅奇祖马布在治疗结性脊柱炎 (AS) 中的脑膜炎方面表现有前途. 乙坦塞普特可能会增加卵膜炎的风险,而单独使用IL-17A抑制剂的效果不如安慰剂.
科学领域:
- 类风湿病学 类风湿病学
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 尿道炎是结性脊柱炎 (AS) 中常见的关节外表现.
- 了解各种生物药物对紫外线炎的比较疗效对于临床决策至关重要.
研究的目的:
- 进行网络元分析 (NMA),比较抗TNF-α,IL-17和JAK抑制剂,用于AS新发性和复发性脑膜炎.
- 根据相对风险和积累性排名曲线 (SUCRA) 下的表面,对这些生物制剂的疗效进行排名.
主要方法:
- 网络二/三期随机对照试验和队列研究的元分析 (NMA).
- 包括抗TNF-α (阿达利马布,埃坦塞普特,戈利马布,因弗利西马布),IL-17抑制剂 (塞库金马布,比米基祖马布,伊克齐祖马布) 和JAK抑制剂 (托法西提尼布,乌帕达西提尼布).
- 估计相对风险 (RR) 和计算SUCRA的药物疗效排名.
主要成果:
- 对于新发性脑膜炎,阿达利穆马布降低了风险,而不是以太那塞普特/戈利穆马布;以太那塞普特增加了风险,而不是戈利穆马布/因弗力西马布. 乌帕达西替尼的疗效最高 (SUCRA 84.0%),而伊克齐祖马布的疗效最低 (8.7%).
- 对于复发性脑膜炎,阿达利穆马布降低了风险,而不是埃坦塞普特;埃坦塞普特增加了风险,而不是戈利穆马布/因弗力西马布. 比梅基祖马布 (160/320毫克) 显示出最高的疗效 (SUCRA ~83.7%).
- 伊克西祖马布和塞库金努马布在新发病和复发性脑膜炎中效果不如安慰剂.
结论:
- 在AS患者的新发性脑膜炎中,JAK抑制剂似乎更有效.
- 比梅基祖马布抑制IL-17A和IL-17F,显著降低了脑膜炎的风险,与单独的IL-17A抑制剂 (secukinumab,ixekizumab) 不同.
- 与其他TNF-α抑制剂相比,etanercept与胰腺炎的风险增加有关.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
238
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
238
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
180
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
180
Inflammatory Bowel Disease IV: Pharmacological Management
200
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
200
Genome-wide Association Studies-GWAS
14.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
275
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
275
Nephrotic Syndrome II : Assessment and Medical Management
24
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
24


